肾移植活体供者受者采用巴利昔单抗-西罗莫司-泼尼松诱导方案，随后延迟给予低剂量环孢素。 - Suppr

Suppr

超能文献

Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors.

作者信息

Langer R M, Hong D M, Katz S M, Van Buren C T

机构信息

Division of Immunology and Organ Transplantation, University of Texas-Houston, Houston, Texas, USA.

出版信息

Transplant Proc. 2002 Dec;34(8):3162-4. doi: 10.1016/s0041-1345(02)03565-0.

DOI:10.1016/s0041-1345(02)03565-0

PMID:12493406

Abstract

摘要

相似文献

Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors.

Transplant Proc. 2002 Dec;34(8):3162-4. doi: 10.1016/s0041-1345(02)03565-0.

The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.

Transplantation. 2004 Sep 27;78(6):904-10. doi: 10.1097/01.tp.0000134399.10352.e4.

Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients?

Transplant Proc. 2005 Mar;37(2):822-6. doi: 10.1016/j.transproceed.2004.12.121.

Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors.

Transplant Proc. 1999 Feb-Mar;31(1-2):1210-3. doi: 10.1016/s0041-1345(98)02094-6.

Basiliximab widens the therapeutic window for AUC-monitored neoral therapy early after kidney transplantation.

Transplant Proc. 2003 Nov;35(7):2409-11. doi: 10.1016/j.transproceed.2003.08.005.

Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients.

Transplant Proc. 2001 Nov-Dec;33(7-8):3172-3. doi: 10.1016/s0041-1345(01)02350-8.

Effect of basiliximab on renal allograft rejection within 1 year after transplantation.

Transplant Proc. 2006 Sep;38(7):2025-8. doi: 10.1016/j.transproceed.2006.06.026.

Simulect, Neoral, Cellcept, and prednisone in kidney recipients with delayed graft function: a prospective controlled study.

Transplant Proc. 2001 Nov-Dec;33(7-8):3762-3. doi: 10.1016/s0041-1345(01)02592-1.

Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation: preliminary results of a pilot study.

Transplant Proc. 2001 Nov-Dec;33(7-8):3223-5. doi: 10.1016/s0041-1345(01)02371-5.

Efficacy and safety of basiliximab in pediatric renal transplantation.

Transplant Proc. 2002 Feb;34(1):102-3. doi: 10.1016/s0041-1345(01)02687-2.

引用本文的文献

Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.

Drugs Aging. 2009;26(9):715-37. doi: 10.2165/11316480-000000000-00000.

Benefit-risk assessment of sirolimus in renal transplantation.

Drug Saf. 2005;28(2):153-81. doi: 10.2165/00002018-200528020-00006.

Basiliximab: a review of its use as induction therapy in renal transplantation.

Drugs. 2003;63(24):2803-35. doi: 10.2165/00003495-200363240-00009.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors.

作者信息

Langer R M, Hong D M, Katz S M, Van Buren C T

机构信息

Division of Immunology and Organ Transplantation, University of Texas-Houston, Houston, Texas, USA.

出版信息

Transplant Proc. 2002 Dec;34(8):3162-4. doi: 10.1016/s0041-1345(02)03565-0.

DOI:10.1016/s0041-1345(02)03565-0

PMID:12493406

Abstract

摘要

相似文献

Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors.

Transplant Proc. 2002 Dec;34(8):3162-4. doi: 10.1016/s0041-1345(02)03565-0.

The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.

Transplantation. 2004 Sep 27;78(6):904-10. doi: 10.1097/01.tp.0000134399.10352.e4.

Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients?

Transplant Proc. 2005 Mar;37(2):822-6. doi: 10.1016/j.transproceed.2004.12.121.

Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors.

Transplant Proc. 1999 Feb-Mar;31(1-2):1210-3. doi: 10.1016/s0041-1345(98)02094-6.

Basiliximab widens the therapeutic window for AUC-monitored neoral therapy early after kidney transplantation.

Transplant Proc. 2003 Nov;35(7):2409-11. doi: 10.1016/j.transproceed.2003.08.005.

Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients.

Transplant Proc. 2001 Nov-Dec;33(7-8):3172-3. doi: 10.1016/s0041-1345(01)02350-8.

Effect of basiliximab on renal allograft rejection within 1 year after transplantation.

Transplant Proc. 2006 Sep;38(7):2025-8. doi: 10.1016/j.transproceed.2006.06.026.

Simulect, Neoral, Cellcept, and prednisone in kidney recipients with delayed graft function: a prospective controlled study.

Transplant Proc. 2001 Nov-Dec;33(7-8):3762-3. doi: 10.1016/s0041-1345(01)02592-1.

Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation: preliminary results of a pilot study.

Transplant Proc. 2001 Nov-Dec;33(7-8):3223-5. doi: 10.1016/s0041-1345(01)02371-5.

Efficacy and safety of basiliximab in pediatric renal transplantation.

Transplant Proc. 2002 Feb;34(1):102-3. doi: 10.1016/s0041-1345(01)02687-2.

引用本文的文献

Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.

Drugs Aging. 2009;26(9):715-37. doi: 10.2165/11316480-000000000-00000.

Benefit-risk assessment of sirolimus in renal transplantation.

Drug Saf. 2005;28(2):153-81. doi: 10.2165/00002018-200528020-00006.

Basiliximab: a review of its use as induction therapy in renal transplantation.

Drugs. 2003;63(24):2803-35. doi: 10.2165/00003495-200363240-00009.